- Home
- GP vs RNAZ Comparison
GP vs RNAZ Comparison
Compare GP & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GP
- RNAZ
- Stock Information
- Founded
- GP 2010
- RNAZ 2016
- Country
- GP Canada
- RNAZ United States
- Employees
- GP N/A
- RNAZ N/A
- Industry
- GP Construction/Ag Equipment/Trucks
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- GP Consumer Discretionary
- RNAZ Health Care
- Exchange
- GP Nasdaq
- RNAZ Nasdaq
- Market Cap
- GP 9.4M
- RNAZ 8.7M
- IPO Year
- GP 2020
- RNAZ 2021
- Fundamental
- Price
- GP $2.69
- RNAZ $12.69
- Analyst Decision
- GP
- RNAZ Strong Buy
- Analyst Count
- GP 0
- RNAZ 1
- Target Price
- GP N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- GP 34.0K
- RNAZ 421.6K
- Earning Date
- GP 11-13-2025
- RNAZ 11-13-2025
- Dividend Yield
- GP N/A
- RNAZ N/A
- EPS Growth
- GP N/A
- RNAZ N/A
- EPS
- GP N/A
- RNAZ N/A
- Revenue
- GP $18,399,688.00
- RNAZ N/A
- Revenue This Year
- GP $81.12
- RNAZ N/A
- Revenue Next Year
- GP $91.69
- RNAZ N/A
- P/E Ratio
- GP N/A
- RNAZ N/A
- Revenue Growth
- GP N/A
- RNAZ N/A
- 52 Week Low
- GP $2.28
- RNAZ $6.15
- 52 Week High
- GP $14.12
- RNAZ $568.26
- Technical
- Relative Strength Index (RSI)
- GP 47.15
- RNAZ 48.74
- Support Level
- GP $2.71
- RNAZ $12.11
- Resistance Level
- GP $2.97
- RNAZ $13.92
- Average True Range (ATR)
- GP 0.20
- RNAZ 1.26
- MACD
- GP -0.12
- RNAZ -0.24
- Stochastic Oscillator
- GP 6.76
- RNAZ 15.14
About GP GreenPower Motor Company Inc.
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.